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Introduction
Detrusor Sphincter Dyssynergia. Storage and emptying of urine from the bladder are dependent on coordinated contraction/relaxation of the smooth and striated muscles in lower urinary tract organs mediated by neural circuitry in the brain and spinal cord 1 .
During storage, detrusor smooth muscle is relaxed, while the smooth and striated muscles of external urethral sphincter (EUS) contract to maintain continence. The converse happens during micturition, when the detrusor smooth muscle contracts and the EUS relaxes. This voluntary control of micturition is lost following spinal cord injury (SCI) rostral to the lumbosacral spinal segments, and the bladder becomes areflexic. Following recovery from spinal shock, reflex bladder activity re-emerges with the formation of a spinal micturition pathway, and ultimately the bladder becomes hyperreflexic 2 . SCI also leads to detrusor sphincter dyssynergia (DSD) which describes the simultaneous contraction of the bladder and EUS. DSD is commonly attributed to the interruption of descending inhibitory pathways from the pontine micturition center (PMC) to EUS motoneurons in Onuf's nuclei within the sacral spinal cord. Various therapies have been employed to reduce DSD; however, the results have failed to satisfy the Level 1 recommendation 3 . DSD causes urinary retention-a major problem in the care of SCI patients. The resultant high intravesical pressures can induce ureteral reflux and potentially lead to renal failure.
Detrusor Overactivity (DO) . Urinary retention, bladder distention and inflammation, secondary to DSD-induced outlet obstruction, lead to bladder wall hypertrophy and DO, where the latter has neurogenic and myogenic components. Neurogenic detrusor overactivity (NDO) results from neural remodeling and afferent sensitization, whereas myogenic DO occurs due to a combination of increased coupling of putative pacemaker interstitial cells and detrusor smooth muscle and stretch-evoked urothelial ATP release 4 .
Increased myogenic activity may also stimulate mechanosensitive afferents 5 to trigger reflex bladder contractions and exacerbate NDO symptoms.
Neurotrophic factors and p75 NTRs . Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are released by detrusor smooth muscle, mast cells and urothelial cells in various pathologies 6 . Mature NGF and BDNF are enzymatically processed within secretory vesicles from their proneurotrophins (proNGF/proBDNF) before release 7 . During pathology 8 , their overexpression exceeds the rate of processing leading to unregulated release of proneurotrophins which differ from mature forms in their affinity for p75 NTRs , the expression of which is increased following SCI in the bladder and neuronal pathways governing micturition 9 . Furthermore, proNGF/proBDNF preferentially activate the p75 NTR -sortilin complex. Sortilin is transport protein involved in the organization of intracellular cargo between membrane compartments, that when activated by proneurotrophins in conjunction with p75 NTR can induce apoptosis in many cell types 10 . The mature neurotrophins activate their cognate tropomyosin receptor kinase (Trk) and p75 NTR heterodimer, promoting survival and differentiation ( Figure 1A) .
Upon proneurotrophin binding, full-length p75 NTRs undergo proteolytic cleavage, removing the extracellular domain (ECD) and leaving the membrane bound carboxylterminal fragment. Further cleavage generates the soluble intracellular domain (ICD), which can translocate to the nucleus 11 , activating apoptotic transcriptional targets in addition to pathways activated by the full-length p75 NTR 10 .
LM11A-31 and LM11A-24. These are small organic molecules identified as modulators of p75 NTRs through in silico screening for potential to mimic the binding activity of the loop 1 domain of NGF and competitively antagonize proneurotrophin binding 12 .
However, these molecules can also have the potential to directly activate p75 NTR associated signaling 13 . LM11A-31 partitions mostly to the CNS and has been shown to improve motor coordination after spinal cord contusion injury in mice 14 . The absence of toxicity or exacerbation of injury-associated pain 14 in previous studies using LM11A-31 affirms its possible therapeutic potential for treating neurogenic LUTD. Therefore, our aim was to determine the effect of oral administration of LM11A-31 on LUTD in a thoracic SCI mouse model.
Methods

SCI surgery (T8-T9 transection)
. SCI surgery was performed as previously described 5 . Briefly, adult female C57BL/6 mice (18-25 g) were anesthetized with isoflurane (5% induction/1.5% maintenance) and a laminectomy performed at the T8-T9 spinal level. The cord was completely transected, the resultant space between the cut ends filled with hemostatic sponge to minimize bleeding and the muscle layer and overlying skin sutured. Subsequently, bladders were expressed by gentle abdominal compression, twice-daily, for one week. The animals were used for experiments one day to six weeks following SCI.
LM11A-31 and LM11A-24 treatment. Both LM11A-31 and LM11A-24 were synthesized in house. Mice were administered once-daily gavage of water (100 μl) in controls and aqueous solutions of LM11A-31 or LM11A-24 (100 mg/kg) in treated groups.
Treatment was initiated either a day before or seven days after SCI, until experimental endpoints. Spinal cord intact mice were also administered the drugs or vehicle for a seven day period, a week following SCI.
Histology. Mice were sacrificed according to the University's Institutional Animal Care and Use Committee approved methods, urinary bladders dissected and opened longitudinally along the ventral aspect, flattened, fixed overnight in 10% paraformaldehyde, embedded in paraffin, sectioned transversely (3 μm) and stained with hematoxylin and eosin or 2% acidified toluidine blue (mast cell stain) for light microscopy.
Enzyme linked immunosorbent assay (ELISA). Urine samples were collected from the bladders of mice immediately following euthanasia using a 32-gauge insulin syringe, and immediately frozen on dry ice and stored at -80ºC. Levels of p75 NTR ECD were evaluated using a mouse NGFR/p75 ECD rapid ELISA kit (Biosensis) according to manufacturer instructions.
Western blotting. The mucosa and detrusor muscle layers were separated by blunt dissection, and samples were homogenized (Lysing Matrix D using FastPrep-24, MP Biomedicals) in Hank's balanced salt solution containing complete protease inhibitor cocktail (1 tablet/10 ml, Roche) and phosphatase inhibitor cocktail (Sigma, 1:100). After centrifugation (10,000 x g; 15 min at 4ºC), the supernatant was collected, and the membrane protein fraction was prepared by suspending pellets in lysis buffer (0.3 M NaCl, 50 mM Tris-HCl pH7.6 and 0.5% Triton X-100) with protease/phosphatase inhibitors as above. Supernatants were pooled for whole cell lysates and protein concentrations determined using a BCA protein assay (Pierce). After denaturation (100ºC for 5 min) in Laemmli sample buffer, 40 µg of each lysate was separated on a 4-15% TGX Stain-Free SDS-PAGE gel (Bio-Rad). Proteins were transferred to PVDF membranes and incubated overnight at 4ºC with primary antibodies against the ICD of p75 NTR , proNGF, proBDNF and β-actin (details of antibodies in supplemental figure 13) diluted in Tris-buffered saline with 0.1% Tween-20 (TBS-T) containing 5% (w/v) milk.
Membranes were incubated with appropriate horseradish peroxidase conjugated secondary antibodies in 5% (w/v) Milk TBS-T, washed, and incubated in WesternBright Quantum (Advansta) for chemiluminescent imaging (ChemiDoc MP, Bio-Rad). Optical density of each protein species was normalized to total protein levels using Image Lab software (Bio-Rad).
Immunofluorescence. Whole bladders and spinal cord segments were isolated, embedded in optimal cutting temperature medium and frozen on dry ice (n=3 per group).
The bladders were sectioned (10 μm) on a cryostat and immediately processed for immunofluorescent detection of p75 NTRs , tyrosine hydroxylase (TH) and calcitonin gene related protein (CGRP) using a previously described protocol 15 . The p75 NTR expression and p75 NTR -CGRP/TH colocalization analysis were performed using ImageJ (NIH) and MATLAB (MathWorks Inc.) software, respectively.
Urine spot assay. Mice were placed individually in clean metabolic cages lined with
Whatman filter paper at the bottom for two hours, between 11 a.m. and 2 p.m., with water and food withheld for the duration of the assay. The filter papers were visualized under UV light, images retained as TIFF files and analyzed using ImageJ software using a previously described method 16 (see supplemental figure 8 ).
Transepithelial resistance (TER) measurements. Following euthanasia, bladders were excised, washed with oxygenated Ringer's solution, opened to form a sheet, mounted on a nylon ring (0.09 cm 2 exposed area) and placed in Ussing chambers under constant oxygenation and temperature control. TER was determined by passing current through Ag/AgCl electrodes and measuring the voltage deflection (Vt) with another pair of electrodes. Data were digitized for display, analysis and storage.
Decerebrate CMG and EMG recordings. Mice were anesthetized using isoflurane and an incision made in the neck to expose the carotid arteries and trachea. Ligatures were placed around the carotids to decrease cerebral blood flow and a tracheotomy performed using PE-60 tubing. After a craniotomy, the brain rostral to the supracollicular level was sectioned. Decerebration allowed cystometric assessment to be performed without anesthetics which can block reflex bladder contractions. A PE-50 catheter was inserted through the bladder dome, secured using a suture and connected to a pressure transducer and syringe pump. Two stainless steel 50 μm electrodes were inserted transperineally 1 mm lateral to the urethra to record EUS activity. The bladder was emptied manually and then filled with saline at 0.01 ml/min until reflex contractions were elicited to perform voiding cystometry.
Statistical Analysis. Quantitative data are shown as mean ± SD. One and two-way ANOVA was used to determine between group differences with Tukey's multiple comparisons test, differences between data sets were tested with unpaired Student's ttest, and skewed data sets with a Mann-Whitney U test; significance was p<0.05. 
Results
LM11A-31 improves voiding efficiency. In vivo voiding patterns were assessed
using urine spot test analysis over a two-hour period ( Figure 2 and Supplemental Figure   7 ). Spinal cord intact mice were continent and voided in one area of the cage ( Figure   2A ). Voiding patterns and voided volumes of spinal cord intact mice were not affected by daily administration of LM11A-24 ( Figure 2B ) or LM11A-31 ( Figure 2C ), the maximal dosage shown to improve motor recovery following spinal cord contusion injury 14 . Two weeks post-SCI, mice exhibited random urine spots and a significant decline in voided volumes ( Figure 2D ). Daily treatment with the peripherally acting LM11A-24 17 did not affect these parameters ( Figure 2E Figure 4D ). These changes were prevented by daily LM11A-31 treatment ( Figure 4E ). The loss of barrier function in SCI animals was apparent from a significant reduction of transepithelial resistance (TER) and this adverse event was prevented by administration of either LM11A-24 or LM11A-31 initiated prior to SCI ( Figure 4F ).
Toluidine blue staining demonstrated that the numbers of activated mast cells in SCT bladders two weeks following injury were significantly greater than in control uninjured bladders (8.1 ± 1.6 cells/mm 2 versus 1.4 ± 1.6 cells/mm 2 , respectively, p < 0.01, unpaired Student's t-test). Daily treatment with LM11A-31 initiated one day before SCI significantly decreased the mast cell numbers (3.2 ± 1.7 cells/mm 2 , p < 0.01 versus untreated SCI).
LM11A-24 treatment also decreased the number of activated mast cells, but less significantly (6.5 ± 2.2 cells/mm 2 , p = 0.05 versus untreated SCI).
Alteration in p75 NTR and proneurotrophin levels in the urine and urinary bladder following SCI. Urine levels of p75 NTR ECD were evaluated by ELISA, one to seven days following SCI ( Figure 4G ). A sharp rise in p75 NTR ECD levels noted one day post-injury, was decreased by LM11A-31 pretreatment, SCI-induced elevations of the p75 NTR ECD were observed at much lower levels for up to seven days post-injury.
Western blot analysis showed full-length p75 NTRs are more highly expressed in the detrusor than the mucosa and these levels are decreased at seven days post SCI.
LM11A-31 treatment blocked the loss of p75 NTR expression in SCI animals ( Figure 4H and I). LM11A-31 treated mice had elevated proBDNF levels compared to untreated SCI and control mice. The protein level of proNGF was not significantly different in the mucosa or detrusor samples from control, SCI and SCI + LM11A-31 groups (data not shown). The p75 NTR and proBDNF levels normalized to β-actin are summarized in the bar graphs in Figure 4I . treatment of SCI mice did not significantly alter total p75 NTR expression in the urothelium or detrusor, nor the colocalization of p75 NTR with CGRP or TH compared to untreated SCI mice ( Figure 5J and K). The % area of p75 NTR expression in the urothelium did not differ between spinal cord intact (1.2 ± 0.6 %), SCI (2.3 ± 2.3%) and SCI mice with LM11A-31 (1.4 ± 1.3%) or LM11A-24 (2.2 ± 0.8%) treatment. In control mice, expression of p75 NTR in L6-S1 spinal cord segment was limited to the dorsal horn (45.0 ± 11.0% of dorsal horn area) with the highest density in the lamina-II region ( Figure 5G ). At seven days post-SCI, there was a significant decrease in p75 NTR expression in the lamina-II region of the dorsal horn (from 77.8 ± 16.8% in controls to 44 ± 19.6% of lamina-II area) ( Figure 5H ), which was not altered by LM11A-31 treatment (42.0 ± 3.7%) ( Figure 5I ).
Discussion
SCI-induced LUTD is described by the symptoms and signs including DSD, NDO, myogenic DO, and urothelial barrier disruption, hypertrophy and hyperplasia. These physiological and histological changes correlate with increased production of proNGF/proBDNF by denervated tissues within the spinal cord and bladder wall following SCI 18 .
The expression of p75 NTRs is previously reported to be localized in urothelium of rat bladders 19 and in SCI patient biopsies 9 , where p75 NTRs likely contribute to the urothelial injury in SCI. Our study suggests that under normal conditions, there is robust expression of p75 NTRs in the urinary bladder where a select population colocalize with CGRP and THpositive innervating the mouse urothelium and detrusor (Figures 5A, D and K) some of which could potentially originate from bladder innervating neurons in L1 and S1 dorsal root ganglia (supplemental figure 11 ). LM11A-31 treatment did not affect the decrease in p75 NTR or the % colocalization with TH or CGRP, suggesting this drug may be altering functional properties of bladder nerves to bring about their therapeutic effect. SCI have been shown to enhance bladder sensory neuron firing due to increased Na + channel currents density and a similar effect has been demonstrated with chronic intrathecal NGF administration 2 . The effect of LM11A-31 on bladder afferent firing has yet to be determined, however, our data show that treatment can ameliorate SCI-induced DO and significantly improve bladder compliance, suggesting an effect on afferent activity.
Following SCI, there is increased p75 NTR expression in the basal/intermediate urothelium ( Figure 5M ) which could correlate with proliferating cells found during the first seven days after SCI 20 . This suggests neurotrophin signaling may be involved in maintaining urothelial differentiation or regeneration of the urothelium following injury. Strong p75 NTR expression is also noted in the dorsal horn of L6-S1 spinal cord segments ( Figure 5G ), as reported previously 21 . The high level of p75 NTR in the detrusor layer noted in western blots ( Figure 4H -I) could be due to higher density of p75 NTR positive nerve fibers compared to the mucosa ( Figure 5 ). Studies with urothelial NGF overexpressing mice 22 also showed enhanced expression of p75 NTR in the detrusor layer compared to control mouse bladders. Our data demonstrate that p75 NTR ECD fragments are elevated in acute SCI ( Figure 4G ), suggesting that binding of proneurotrophins is inducing the p75 NTR cleavage.
However, we cannot rule out that some of the ECD protein excreted in the urine may be contributed by other organs/tissues. Pretreatment with LM11A-31 blocked the rise of urinary p75 NTR ECD levels that occurs within 24 hours of SCI, suggesting LM11A-31 treatment in the clinical setting may be most beneficial within hours following SCI to prevent the activation of neurodegenerative pathways. Nonetheless, we have also demonstrated that LM11A-31 ameliorated DSD and DO when given one week following SCI ( Figure 3C ). Our data showed a significant decline in measurable amounts of proBDNF by seven days post-SCI and this decline was not observed in LM11A-31 treated groups ( Figure 4I ) suggesting displacement of proBDNF by LM11A-31 raises the levels of free proBDNF. This trend was not observed with proNGF, whose production in bladder was lower than proBDNF (not shown). There may be multiple factors (e.g. inflammation induced mRNA instability, disruption in protein translation mechanisms) that could be attributed to decreased proneurotrophin levels in SCI. Enhanced uptake and retrograde transport of neurotrophins from the bladder, proposed for changes in NGF levels following SCI 23 , could potentially be involved. As LM11A-31 treatment prevented the decline in proBDNF, it suggests the drug is preventing proneurotrophin binding and subsequent transport, supporting the concept of SCI-induced alterations in neurotrophin uptake.
We propose that unregulated release of proNGF/proBDNF from vesicular stores 24 stimulates p75 NTR -positive nerves and the urothelium to initiate degenerative pathways.
The consequent urothelial disruption, urine infiltration and inflammation lead to increased release of excitatory transmitters 25 from sensory nerves that further potentiates the inflammatory processes to promote afferent sensitization and exacerbation of NDO. The urothelium shows constitutive expression of NGF which is believed to participate in maintaining normal bladder function 25 . During the acute phase of SCI, it could be speculated that urothelial disruption and nerve injury causes a rapid increase in neurotrophin expression 23 . Our data suggest proneurotrophin signaling predominates within 24 hours following SCI and may be responsible for the detrimental p75 NTR signaling in the bladder. At later time points following SCI, there may be proportionally more mature neurotrophins in the bladder than under normal conditions 23 as a compensatory mechanism to promote nerve growth. Loss of bladder and L6-S1 p75 NTR expression in SCI suggests impairment of afferent and efferent function in the bladder precedes the urinary retention noted acutely following injury. Loss of nerve fibers is also noted in bladders of SCI patients 26 . Activation of p75 NTR leads to receptor internalization and retrograde axonal transport to induce transcriptional changes 27 and may account for decreased p75 NTR expression in the bladder following SCI. LM11A-31 treatment did not change bladder or L6-S1 spinal cord p75 NTR expression compared to vehicle treated SCI mice (supplemental figure 12 ), suggesting it may rather augment sensory nerve activity in the dorsal root ganglia or L3-L4 EUS centers to ameliorate SCI-induced DO and DSD.
The actions of LM11A-31 and LM11A-24 were compared to elucidate the sites of action responsible for the observed effects, because LM11A-31 crosses the blood-brain barrier 14 and may act on the CNS and periphery, whilst LM11A-24 has mainly peripheral actions 14, 17 . Both agents did not alter voiding patterns when given to animals with intact spinal cords ( Figures 2B, C) . In SCI animals, LM11A-31, but not LM11A-24, was able to ameliorate NDO and DSD and increase voided volumes ( Figure 2F and E, respectively and Supplemental Figure 7 ). However, both LM11A-24 and LM11A-31 could prevent urothelial barrier disruption ( Figure 4F ), demonstrating a shared peripheral site of action for both ligands. Preventing urothelial disruption may account for the decreased number of activated mast cells in the bladder wall, however, mast cells also express p75 NTR and we cannot exclude a direct effect of p75 NTR modulators on these cells. We infer that central actions of LM11A-31 are critical for the improvement of DSD and NDO and peripheral actions of the drug may further augment the central effects.
Based on our findings, a description of our hypothesis for the development of SCIinduced DSD and NDO and putative therapeutic sites of action of LM11A-31/24 are shown in supplemental figure 6.
Conclusion
The proposed therapeutic use of LM11A-31 to treat SCI-induced LUTD is clinically relevant as there are currently no pharmacological agents to treat DSD. This agent also has therapeutic effect on NDO, can be administered orally and is safe and has entered phase II clinical trials for Alzheimer's disease 28 . Colocalization analysis of p75 NTR CGRP and K) TH immunofluorescence. The % area that overlapped between p75 NTR and CGRP or p75 NTR and TH immunofluorescence were quantified using MATLAB software within the total bladder wall area as defined by DAPI staining. L) p75 NTR and CGRP expressing fiber in SC intact mouse urothelium (white bordered region). M) p75 NTR expression in urothelial basal layer of SCI mouse bladders which was not found in SC intact mice. Similar urothelial staining profile was also seen with SCI + LM11A-31 and SCI + LM111A-24 treated mice. Graphical representation of % area expression of p75 NTR in the bladder wall and L6-S1 dorsal horn are shown in supplemental figure 12.
Figure legends
Supplemental figure 6. Mechanisms of proneurotrophins in SCI-induced LUTD and amelioration by LM11A-31 and -24.
A) The p75 NTR signals through dimerization with sortilin or Trk receptors. p75 NTR -sortilin complexes will preferentially bind proNGF/proBDNF that activate apoptotic signaling cascades. Conversely, p75 NTR -Trk receptors bind to mature neurotrophins to activate cell survival pathways. Table 1) Neurotrophin receptors and their ligands. B-C) Schematic of neural connections that regulate voiding and the alterations following SCI that contribute to DSD and bladder dysfunction). B) Under normal conditions, the urinary bladder and EUS receive parasympathetic inputs from the L6-S1 spinal cord via pelvic and pudendal nerves, respectively. These inputs are regulated by supraspinal sites to coordinate afferent input [1] to the PMC that results in outflow to parasympathetic neurons [2] for bladder contraction and activation of inhibitory neurons [3] that act on motoneurons in Onuf's nuclei to relax the EUS. In rodents, there are also inhibitory interneurons in the L3-L4 region that project to Onuf's nuclei to promote EUS bursting [4] and death of these inhibitory interneurons may contribute to the development of DSD. C) Data in Figure 5G -I demonstrate the selective expression of p75 NTRs in the dorsal horn of a mouse L6 spinal cord segment whose selective stimulation by LM11A-31 leads to the remodelling that we hypothesize includes afferent projections to parasympathetic efferent nerves [5] that accounts for the bladder to spinal cord reflex. We propose that the action of LM11A-31 on cell pro survival signaling pathways allows it to promote growth of afferent projections to the L3-L4 region [7] and preserve the survival of inhibitory neurons in the L3-L4 region to alleviate DSD. [8] LM11A-31 prevents proneurotrophin binding to p75 NTRs on sympathetic and sensory nerve endings in the bladder wall, to prevent urothelial disruption and afferent sensitization and the development of NDO, respectively.
Supplemental Figure 7 . Voided volumes calculated from spot tests using ImageJ.
Supplemental Figure 8 . Calibration data for spot test analysis. Supplemental Figure 10 . Values of contraction duration (CD), voiding duration (VD) and EUS bursting activity in control, 2 weeks SCI and 2 weeks SCI with LM11A-31 therapy started a week following injury (n≥4). (*p<0.01 compared to both control and 2 weeks SCI with LM11A-31 therapy, unpaired Student's t-test).
Supplemental Figure 11 . Coexpression of p75 NTR and TH or CGRP in DRG neurons innervating the mouse urinary bladder. Bladders of SC intact mice were injected with 10 µl of 2% fast blue solution and L1 and S1 DRG were isolated after one week and examined for expression of p75 NTR and TH or CGRP on bladder specific sensory neurons by immunofluorescence. A) p75 NTR and TH were found to colocalize on neurons in L1 DRG which send projections to the bladder through the hypogastric nerve (white arrows).
B) S1 DRG (that send projections via pelvic nerve) also showed a small number of fast blue labeled sensory neurons that colocalized with p75 NTR and TH (white arrow). These indicate that some p75 NTR + TH-positive fibers in the bladder could be from sensory neurons. In C) L1 DRG and D) S1 DRG, p75 NTR and CGRP were found to colocalize on fast blue labeled neurons (white arrows).
Supplemental Figure 12 . Quantification of p75 NTR expression in the urothelial and detrusor layers and L6-S1 spinal cord segment. Figure 12 Primary Antibodies ( Figure 13 
